Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

NCT02767661 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

263

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Capecitabine
DRUG: Aromatase Inhibitor

Sponsor

Sun Yat-sen University

Collaborators

[object Object]